» Authors » M K Wild

M K Wild

Explore the profile of M K Wild including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 241
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wild M, Huang M, van der Merwe P, Vestweber D
J Biol Chem . 2001 Jun; 276(34):31602-12. PMID: 11404363
E-selectin is an endothelial adhesion molecule, which mediates the tethering and rolling of leukocytes on vascular endothelium. It recognizes the glycoprotein E-selectin ligand-1 (ESL-1) as a major binding partner on...
2.
Luhn K, Wild M, Eckhardt M, Gerardy-Schahn R, Vestweber D
Nat Genet . 2001 Apr; 28(1):69-72. PMID: 11326279
Leukocyte adhesion deficiency II (LAD II) is characterized by the lack of fucosylated glycoconjugates, including selectin ligands, causing immunodeficiency and severe mental and growth retardation. No deficiency in fucosyltransferase activities...
3.
Wild M, Strittmatter W, Matzku S, Schraven B, Meuer S
J Immunol . 1999 Aug; 163(4):2064-72. PMID: 10438945
For tumor therapy with unprimed effector cells, we developed a novel combination of a CD2 x tumor Ag bispecific targeting Ab and an anti-CD2 triggering Ab. These Ab constructs were...
4.
Wild M, CAMBIAGGI A, Brown M, Davies E, Ohno H, Saito T, et al.
J Exp Med . 1999 Aug; 190(1):31-41. PMID: 10429668
The T cell antigen receptor (TCR) and its ligand peptide-major histocompatibility complex (MHC) are small (approximately 7 nm) compared with other abundant cell surface molecules such as integrins, CD43, and...
5.
Davis S, Ikemizu S, Wild M, van der Merwe P
Immunol Rev . 1998 Aug; 163:217-36. PMID: 9700513
Rapid progress has recently been made in characterising the structures of leukocyte cell-surface molecules. Detailed analyses of the structure and interactions of CD2 were the first involving a molecule that...
6.
Wild M, Verhagen A, Meuer S, Schraven B
Cell Immunol . 1997 Oct; 180(2):168-75. PMID: 9341747
The activation of human T cells via CD2 in response to mitogenic monoclonal antibodies (mAbs) typically requires that one mAb is specific for an epitope within the N-terminal Ig domain...